Published • loading... • Updated
Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy
The deal gives Cellular Intelligence access to a first-in-human therapy that has FDA Fast Track designation and could speed development and manufacturing.
- On Monday, Cellular Intelligence acquired global rights to Novo Nordisk's clinical-stage Parkinson's program, STEM-PD, currently in a first-in-human Phase 1/2 clinical trial with FDA Fast Track Designation.
- Novo Nordisk decided last year to wind down cell therapy research to focus on obesity and diabetes treatments like Ozempic and Wegovy; the Danish drugmaker is making a strategic equity investment in Cellular Intelligence as part of the agreement.
- To lead clinical advancement, Cellular Intelligence appointed neurologist Dr. Nuno Mendonça as chief medical officer, and the startup has raised over $60M from investors including Khosla Ventures and the Chan Zuckerberg Initiative.
- Cellular Intelligence plans to initiate a mid-stage study early next year, utilizing its AI-native platform to optimize cell production and compress development timelines.
- This transaction represents a role reversal in traditional pharmaceutical deals, with the startup assuming control of a complex program from a global leader, positioning Cellular Intelligence as a proving ground for applying large-scale biological modeling to regenerative medicine.
Insights by Ground AI
13 Articles
13 Articles
Novo Nordisk hands Parkinson's cell therapy to Zuckerberg-backed Cellular Intelligence
Novo will take an equity stake in Cellular Intelligence and is in line for future milestone payments and royalties. The startup plans to apply its AI platform to STEM-PD, a stem-cell-derived treatment Novo discontinued last October. Novo Nordisk has handed over STEM-PD, an experimental stem-cell therapy for Parkinson’s disease, to Cellular Intelligence, an AI biotech […] This story continues at The Next Web
·Amsterdam, Netherlands (Kingdom of the)
Read Full ArticleCoverage Details
Total News Sources13
Leaning Left5Leaning Right1Center4Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 40%
Factuality
To view factuality data please Upgrade to Premium
